STOCK TITAN

Conmed Corp Stock Price, News & Analysis

CNMD NYSE

Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.

Conmed Corporation (CNMD) delivers innovative medical technologies that enhance surgical outcomes and patient care worldwide. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, financial performance, and product advancements shaping the medical device sector.

Access authoritative information on CNMD's latest earnings reports, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing new product launches in orthopedics, general surgery, and patient monitoring systems, along with updates on global market expansion initiatives.

Stay informed about critical developments through verified announcements directly from Conmed Corporation and third-party analysis. This resource enables stakeholders to track the company's progress in advancing minimally invasive surgical techniques and improving clinical workflows across healthcare institutions.

Bookmark this page for streamlined access to CNMD's evolving role in medical technology innovation. Regularly updated content supports informed analysis of the company's market position and long-term growth trajectory within the competitive healthcare solutions landscape.

Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) is set to report its Q2 2021 financial results on July 28, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested parties can join the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 7138188. The call will also be available via webcast on the CONMED website, and a recording will be accessible from 7:30 p.m. ET on the same day until August 4, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share. This dividend is payable on July 6, 2021, to shareholders of record as of June 15, 2021. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various specialties, including orthopedics and general surgery. For additional details, visit www.conmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
dividends
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported first-quarter 2021 financial results, highlighting a sales increase of 8.7% year-over-year to $232.7 million. Domestic revenue rose 4.3%, while international revenue surged 14.3%. Diluted EPS rose 55.0% to $0.31. The company enhanced its 2021 revenue guidance to between $1.0 billion and $1.03 billion, up from $975 million to $1.02 billion. Adjusted diluted EPS guidance is now $3.05 to $3.20, improved from $2.85 to $3.05.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) will report its first-quarter 2021 financial results after market close on April 28, 2021. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results. Investors can participate by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) using passcode 1487002. The call will also be webcast on the company's website, with a replay available one hour post-call. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has announced its Annual Meeting of Stockholders, to be held virtually on May 19, 2021, at 1:30 p.m. ET. Shareholders of record by March 29, 2021, are eligible to vote. CONMED specializes in medical technology, particularly surgical devices for minimally invasive procedures across various specialties. The company cautions that forward-looking statements may be affected by uncertainties, including the impact of COVID-19 on surgical volumes and supply chains, among other risk factors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announced participation in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at 11:30 a.m. ET. The session will feature Chair and CEO Curt R. Hartman and CFO Todd W. Garner. Investors can access the live webcast via the Company’s website at www.conmed.com, which will be available for replay post-event. CONMED specializes in minimally invasive surgical devices used across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share, payable on April 5, 2021 to shareholders on record as of March 15, 2021.

CONMED is a medical technology company that provides surgical devices for minimally invasive procedures, serving various specialties including orthopedics and neurosurgery. The announcement reflects the company's ongoing commitment to returning value to shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
dividends
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announced participation of Curt R. Hartman, Chair of the Board and CEO, alongside Todd W. Garner, CFO, in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference. The event is scheduled for 9:20 a.m. ET on February 25, 2021.

The live webcast will be available in the ‘Investors’ section of their website, and a replay will be accessible post-event. CONMED is a provider of surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported Q4 2020 sales of $252.8 million, down 4.5% year-over-year, with domestic revenue decreasing 0.7% and international revenue falling 9.1%. Diluted EPS rose to $0.81 from $0.49 in Q4 2019, while adjusted EPS decreased from $0.90 to $0.84. For the full year, sales were $862.5 million, a 9.7% decline, and diluted EPS was $0.32 versus $0.97 in 2019. The company expects 2021 revenue between $975 million and $1.02 billion, with adjusted EPS forecasted at $2.85 to $3.05.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
Rhea-AI Summary

CONMED Corporation (CNMD) will report its fourth quarter and full year 2020 financial results on January 27, 2021, post-market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Participants can join the call by dialing specific numbers provided or via a webcast accessible through the company’s website. A recording of the call will be available for one week following the event. The company specializes in surgical devices for minimally invasive procedures across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags

FAQ

What is the current stock price of Conmed (CNMD)?

The current stock price of Conmed (CNMD) is $44.49 as of October 30, 2025.

What is the market cap of Conmed (CNMD)?

The market cap of Conmed (CNMD) is approximately 1.4B.
Conmed Corp

NYSE:CNMD

CNMD Rankings

CNMD Stock Data

1.45B
30.78M
0.58%
114.87%
6.75%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
LARGO